Last reviewed · How we verify
NCT05104372: HSNIG
Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan
NA trial testing Hypertonic Saline Nasal Irrigation and Gargles (HSNIG) in COVID-19 in 405 participants. Status unknown.
15 November 2021
Quick facts
| Lead sponsor | The Allergy and Asthma Institute, Pakistan |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 405 |
| Start date | 1 May 2021 |
| Primary completion | 15 November 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
The Allergy and Asthma Institute, Pakistan
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nasal washing (washout) followed by gargles with hypertonic saline (HSNIG) is believed to be effective in reducing the duration of illness in those with clinically suspected or confirmed COVID-19 being managed at home, and also is effective in reducing complications of COVID-19 and onward household transmission. This study plans to investigate whether the use of HSNIG performed by adults with symptoms consistent with COVID-19 reduces the duration of symptoms when compared to participants managed using standard care.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy.
Gennari-Felipe M, Borges L, Dermargos A, Weimann E, et al · · 2022 · cited 2× · PMID 35801207 · DOI 10.3389/fmed.2022.917008 -
Hypertonic saline nasal irrigation and gargling for suspected or confirmed COVID-19: Pragmatic randomised controlled trial (ELVIS COVID-19).
Yusuf OM, Ramalingam S, Norrie J, Graham C, et al · · 2024 · PMID 39666578 · DOI 10.7189/jogh.14.05027
Verify or expand the search:
- PubMed search for NCT05104372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05104372 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Allergy and Asthma Institute, Pakistan
- Last refreshed: 3 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05104372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing